Inventor · disambiguated record
Xiaoran Han
Also filed as: HAN XIAORAN
2 granted patents·15 pending applications·1 citations·filing 2018–2025
31Inventor score
Top patents by PatentIndex Score
17 records- 0180US12410171B2Tropomyosin receptor kinase (TRK) degradation compounds and methods of useCULLGEN SHANGHAI INC·Filed 2021·Granted Sep 9, 2025·1 cites·12 claims
- 0278US2025388587A1Tropomyosin receptor kinase (trk) degradation compounds and methods of useCULLGEN SHANGHAI INC·Filed 2025·Application pending·0 cites
- 0376US2024400570A1Tropomyosin receptor kinase (trk) degradation compounds and methods of useCULLGEN SHANGHAI INC·Filed 2024·Application pending·0 cites
- 0469US2024066136A1Modified proteins and protein degradersCULLGEN SHANGHAI INC·Filed 2023·Application pending·0 cites
- 0564US2025325678A1Cyclic-amp response element binding protein (cbp) and/or adenoviral e1a binding protein of 300 kda (p300) degradation compounds and methods of useCULLGEN SHANGHAI INC·Filed 2025·Application pending·0 cites
- 0662US2023057177A1Modified proteins and protein degradersCULLGEN SHANGHAI INC·Filed 2021·Application pending·0 cites
- 0758US2025221988A1Compounds and methods of treating cancersCULLGEN SHANGHAI INC·Filed 2023·Application pending·0 cites
- 0856US2025235543A1Modified proteins and protein degradersCULLGEN SHANGHAI INC·Filed 2022·Application pending·0 cites
- 0954US2024197694A1Modified proteins and protein bindersCULLGEN SHANGHAI INC·Filed 2022·Application pending·0 cites
- 1054US2023073777A1Cyclic-amp response element binding protein (cbp) and/or adenoviral e1a binding protein of 300 kda (p300) degradation compounds and methods of useCULLGEN SHANGHAI INC·Filed 2020·Application pending·0 cites
- 1153US2024050428A1Compounds and methods of treating cancersCULLGEN SHANGHAI INC·Filed 2021·Application pending·0 cites
- 1253US2024100170A1Cyclic-amp response element binding protein (cbp) and/or adenoviral e1a binding protein of 300 kda (p300) degradation compounds and methods of useCULLGEN SHANGHAI INC·Filed 2021·Application pending·0 cites
- 1352US11969472B2Tropomyosin receptor kinase (TRK) degradation compounds and methods of useCULLGEN SHANGHAI INC·Filed 2021·Granted Apr 30, 2024·0 cites·11 claims
- 1452US2024246955A1Tropomyosin receptor kinase (trk) degradation compounds and methods of useCULLGEN SHANGHAI INC·Filed 2022·Application pending·0 cites
- 1552US2024059671A1Tyrosine kinase 2 (tyk2) degradation compounds and methods of useCULLGEN SHANGHAI INC·Filed 2021·Application pending·0 cites
- 1646US2023093099A1Compounds and methods of treating cancersCULLGEN SHANGHAI INC·Filed 2020·Application pending·0 cites
- 1740US2021283261A1Compositions and Methods for Treating ALK-Mediated CancerICAHN SCHOOL MED MOUNT SINAI·Filed 2018·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Xiaoran Han files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →